ANEB

Anebulo Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on developing novel treatments for acute cannabinoid intoxication and substance addiction. Headquartered in Austin, Texas, the company's lead product candidate is ANEB-0001, a synthetic cannabidiol analog designed to rapidly reverse the effects of THC overdose and potentially treat cannabinoid hyperemesis syndrome. The company targets the growing public health concern associated with increased cannabis potency and legalization, addressing a market with no FDA-approved treatments for acute cannabinoid toxicity. Anebulo completed its initial public offering in March 2024, trading on the Nasdaq Capital Market under the ticker symbol ANEB. The company's research pipeline includes investigations into ANEB-0001's potential applications for cannabis use disorder and other substance dependencies. Anebulo maintains strategic collaborations with academic institutions and research organizations to advance its clinical programs. As of its recent filings, the company employs a lean team primarily focused on clinical development and regulatory affairs. The firm completed Phase 1 clinical trials demonstrating safety and tolerability of its lead compound and continues advancing through clinical development stages. Anebulo's business model centers on developing its proprietary cannabinoid receptor technology platform to address unmet medical needs in emergency medicine and addiction treatment settings.